サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1469845

低分子イノベーターAPI CDMOの世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

Global Small Molecule Innovator API CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日: | 発行: Value Market Research | ページ情報: 英文 172 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
低分子イノベーターAPI CDMOの世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
出版日: 2024年04月01日
発行: Value Market Research
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の低分子イノベーターAPI CDMOの市場規模は、2023年に301億6,000万米ドルに達し、2024～2032年の予測期間中にCAGR 7.41%で成長し、2032年には約573億9,000万米ドルに達すると予測されています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、産業の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、低分子イノベーターAPI CDMOの世界市場における各セグメントを包括的に評価することもできます。低分子イノベーターAPI CDMO産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

本セクションでは、低分子イノベーターAPI CDMO市場レポートの国別・地域別セグメントに関する詳細データを提供し、戦略家が各製品・サービスのターゲット層を特定する上で、今後のビジネスチャンスを支援します。

ステージタイプ別

  • 前臨床
  • 臨床
  • 商業

顧客タイプ別

  • 製薬
  • バイオテクノロジー

治療領域別

  • 循環器疾患
  • 腫瘍
  • 呼吸器疾患
  • 神経
  • 代謝疾患
  • 感染症
  • その他

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける低分子イノベーターAPI CDMO市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、著名な全地域における個々の用途セグメントの需要・推定・予測に焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 低分子イノベーターAPI CDMO - 産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 低分子イノベーターAPI CDMOの世界市場分析：ステージタイプ別

  • 概要：ステージタイプ別
  • 実績データと予測データ
  • 分析：ステージタイプ別
  • 前臨床
  • 臨床
  • 商業

第6章 低分子イノベーターAPI CDMOの世界市場分析：顧客タイプ別

  • 概要：顧客タイプ別
  • 実績データと予測データ
  • 分析：顧客タイプ別
  • 製薬
  • バイオテクノロジー

第7章 低分子イノベーターAPI CDMOの世界市場分析：治療領域別

  • 概要：治療領域別
  • 実績データと予測データ
  • 分析：治療領域別
  • 循環器疾患
  • 腫瘍
  • 呼吸器疾患
  • 神経
  • 代謝疾患
  • 感染症
  • その他

第8章 低分子イノベーターAPI CDMOの世界市場分析：地域別

  • 展望：地域別
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 低分子イノベーターAPI CDMO企業の競合情勢

  • 低分子イノベーターAPI CDMOの市場競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Lonza Group Ltd.
  • Novo Holdings（Catalent Inc.）
  • Thermo Fisher Scientific Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • LabCorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences（Jubilant Biosys Ltd.）
  • WuXi AppTec Co. Ltd.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Stage Type (USD MN)
  • Preclinical Market Sales By Geography (USD MN)
  • Clinical (Phase I, Phase II, Phase III) Market Sales By Geography (USD MN)
  • Commercial Market Sales By Geography (USD MN)
  • Analysis By Customer Type (USD MN)
  • Pharmaceutical (Small, Medium, Large) Market Sales By Geography (USD MN)
  • Biotechnology (Small, Medium, Large) Market Sales By Geography (USD MN)
  • Analysis By Therapeutic Area (USD MN)
  • Cardiovascular Diseases Market Sales By Geography (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Respiratory Disorders Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Metabolic Disorders Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Small Molecule Innovator API CDMO Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Small Molecule Innovator API CDMO Report
  • Market Research Process
  • Market Research Methodology
  • Global Small Molecule Innovator API CDMO Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Stage Type
  • Market Attractiveness Analysis By Customer Type
  • Market Attractiveness Analysis By Therapeutic Area
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Stage Type (USD MN)
  • Preclinical Market Sales By Geography (USD MN)
  • Clinical (Phase I, Phase II, Phase III) Market Sales By Geography (USD MN)
  • Commercial Market Sales By Geography (USD MN)
  • Global Market Analysis By Customer Type (USD MN)
  • Pharmaceutical (Small, Medium, Large) Market Sales By Geography (USD MN)
  • Biotechnology (Small, Medium, Large) Market Sales By Geography (USD MN)
  • Global Market Analysis By Therapeutic Area (USD MN)
  • Cardiovascular Diseases Market Sales By Geography (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Respiratory Disorders Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Metabolic Disorders Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114302

The global demand for Small Molecule Innovator API CDMO Market is presumed to reach the market size of nearly USD 57.39 Billion by 2032 from USD 30.16 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule innovator api cdmo. The growth and trends of small molecule innovator api cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule innovator api cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Stage Type

  • Preclinical
  • Clinical (Phase I, Phase II, Phase III)
  • Commercial

By Customer Type

  • Pharmaceutical (Small, Medium, Large)
  • Biotechnology (Small, Medium, Large)

By Therapeutic Area

  • Cardiovascular Diseases
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Diseases
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Innovator API CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Innovator API CDMO market include Lonza Group Ltd., Novo Holdings (Catalent Inc.), Thermo Fisher Scientific, Inc., Siegfried Holding AG, Recipharm AB, CordenPharma International, Samsung Biologics, LabCorp, Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Jubilant Life Sciences (Jubilant Biosys Ltd.), WuXi AppTec Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. SMALL MOLECULE INNOVATOR API CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Stage Type
    • 3.7.2 Market Attractiveness Analysis By Customer Type
    • 3.7.3 Market Attractiveness Analysis By Therapeutic Area
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY STAGE TYPE

  • 5.1. Overview By Stage Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Stage Type
  • 5.4. Preclinical Historic and Forecast Sales By Regions
  • 5.5. Clinical (Phase I, Phase II, Phase III) Historic and Forecast Sales By Regions
  • 5.6. Commercial Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY CUSTOMER TYPE

  • 6.1. Overview By Customer Type
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Customer Type
  • 6.4. Pharmaceutical (Small, Medium, Large) Historic and Forecast Sales By Regions
  • 6.5. Biotechnology (Small, Medium, Large) Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY THERAPEUTIC AREA

  • 7.1. Overview By Therapeutic Area
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Therapeutic Area
  • 7.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
  • 7.5. Oncology Historic and Forecast Sales By Regions
  • 7.6. Respiratory Disorders Historic and Forecast Sales By Regions
  • 7.7. Neurology Historic and Forecast Sales By Regions
  • 7.8. Metabolic Disorders Historic and Forecast Sales By Regions
  • 7.9. Infectious Diseases Historic and Forecast Sales By Regions
  • 7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE INNOVATOR API CDMO COMPANIES

  • 9.1. Small Molecule Innovator API CDMO Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Lonza Group Ltd.
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Novo Holdings (Catalent Inc.)
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Thermo Fisher Scientific Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Siegfried Holding AG
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Recipharm AB
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. CordenPharma International
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Samsung Biologics
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. LabCorp
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Ajinomoto Bio-Pharma Services
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Piramal Pharma Solutions
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Jubilant Life Sciences (Jubilant Biosys Ltd.)
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. WuXi AppTec Co. Ltd.
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies